

Antoine Adenis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7461117/publications.pdf>

Version: 2024-02-01

98
papers

12,967
citations

147726

31
h-index

34964

98
g-index

106
all docs

106
docs citations

106
times ranked

15250
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. <i>Journal of Clinical Oncology</i> , 2022, 40, 382-391.	0.8	13
2	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	2.9	15
3	Regorafenib+avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. <i>European Journal of Cancer</i> , 2022, 162, 161-169.	1.3	22
4	Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4190-TPS4190.	0.8	0
5	REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors+Results of the oesophageal or gastric carcinoma (OGC) cohort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4060.	0.8	1
6	Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4015-4015.	0.8	2
7	Effect of dosimetric parameters on postoperative respiratory morbidity in locally advanced esophageal cancer treated with preoperative chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16075-e16075.	0.8	0
8	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. <i>Future Oncology</i> , 2021, 17, 1143-1153.	1.1	63
9	Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. <i>Value in Health</i> , 2021, 24, 676-682.	0.1	7
10	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 564.	1.1	3
11	Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. <i>Molecular Oncology</i> , 2021, 15, 2401-2411.	2.1	11
12	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. <i>Digestive and Liver Disease</i> , 2020, 52, 347-350.	0.4	2
13	TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?. <i>Lancet Oncology</i> , The, 2020, 21, 1002-1003.	5.1	0
14	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	1.0	9
15	Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard. <i>Journal of Clinical Oncology</i> , 2019, 37, 2379-2379.	0.8	2
16	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1185-1191.	0.4	2
17	Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial. <i>BMJ Open</i> , 2018, 8, e015904.	0.8	12
18	Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?. <i>Radiotherapy and Oncology</i> , 2018, 129, 180-181.	0.3	3

#	ARTICLE	IF	CITATIONS
19	Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. <i>JAMA Oncology</i> , 2018, 4, 887.	3.4	0
20	Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial. <i>BMC Cancer</i> , 2018, 18, 775.	1.1	2
21	Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimen. <i>European Journal of Cancer</i> , 2017, 83, 331-332.	1.3	1
22	Definitive chemoradiation for resectable carcinoma of the cervical esophagus: do we need more evidence?. <i>Annals of Translational Medicine</i> , 2017, 5, 503-503.	0.7	0
23	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016, 16, 412.	1.1	89
24	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) Tj ETQq0 0 2gBT /Overback 10 Tf	1.1	34
25	Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin+folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. <i>BMC Cancer</i> , 2016, 16, 318.	1.1	34
26	First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. <i>Oncology</i> , 2016, 90, 88-96.	0.9	3
27	Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2016, 52, 173-180.	1.3	68
28	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2015, 44, 1141-1147.	0.5	64
29	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
30	Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 305-314.	5.1	318
31	Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. <i>BMC Cancer</i> , 2014, 14, 156.	1.1	32
32	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. <i>Digestive and Liver Disease</i> , 2014, 46, 950-955.	0.4	5
33	Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking. <i>Radiation Oncology</i> , 2013, 8, 24.	1.2	31
34	Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCIO02. <i>BMC Cancer</i> , 2013, 13, 281.	1.1	56
35	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	6.3	2,276
36	Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. <i>BMC Cancer</i> , 2013, 13, 413.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Is Preoperative Chemoradiation With Paclitaxel and Carboplatin a New Standard of Treatment for Esophageal Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 16-17.	0.4	9
38	Regorafenib use as a possible cause of intestinal perforation. <i>Acta Oncologica</i> , 2013, 52, 1789-1790.	0.8	7
39	Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study. <i>Annals of Surgery</i> , 2013, 258, 793-800.	2.1	79
40	Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 23-29.	0.8	394
41	Reply to R. Glynne-Jones et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 165-166.	0.8	2
42	Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2013, 45, 285-294.	1.3	12
43	Prostate cancer related haemophagocytic syndrome: Successful treatment with chemotherapy. <i>Acta Oncologica</i> , 2012, 51, 268-269.	0.8	5
44	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. <i>Clinical Cancer Research</i> , 2012, 18, 4458-4464.	3.2	194
45	Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1941-1948.	0.8	305
46	Advanced Abrikossoff tumour: A metastatic or a multifocal malignancy?. <i>Acta Oncologica</i> , 2012, 51, 133-135.	0.8	9
47	Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: Illustration over a 20-year period. <i>Contemporary Clinical Trials</i> , 2012, 33, 459.	0.8	10
48	Role of the investigator in phase 1 trials of anticancer drugs. <i>Lancet Oncology</i> , The, 2012, 13, 1177-1179.	5.1	0
49	Management of unfavourable carcinoma of unknown primary site: Synthesis of recent literature. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 213-223.	2.0	31
50	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. <i>Medical Oncology</i> , 2012, 29, 3003-3008.	1.2	13
51	Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?. <i>Bulletin Du Cancer</i> , 2012, 99, E100-E106.	0.6	14
52	Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 40-50.	2.0	114
53	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	0.7	57
54	Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. <i>Investigational New Drugs</i> , 2012, 30, 653-661.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials. PLoS ONE, 2012, 7, e52638.	1.1	4
56	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	13.9	6,140
57	Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship?. International Journal of Radiation Oncology Biology Physics, 2011, 81, e39-e47.	0.4	85
58	Metastatic pancreatic cancer: old drugs, new paradigms. Current Opinion in Oncology, 2011, 23, 390-395.	1.1	32
59	A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Investigational New Drugs, 2011, 29, 1021-1028.	1.2	121
60	Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. Investigational New Drugs, 2011, 29, 1414-1419.	1.2	30
61	Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer, 2011, 11, 72.	1.1	101
62	Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Radiation Oncology, 2011, 6, 124.	1.2	11
63	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Investigational New Drugs, 2010, 28, 76-82.	1.2	26
64	Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Investigational New Drugs, 2010, 28, 178-184.	1.2	6
65	Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Investigational New Drugs, 2010, 28, 529-530.	1.2	15
66	Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. Investigational New Drugs, 2010, 28, 839-843.	1.2	5
67	Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer, 2010, 116, 1827-1837.	2.0	46
68	Individual Life Expectancy Estimation Using Validated Prognostic Scores for Patients with Cancer of Unknown Primary. Oncology, 2010, 78, 87-93.	0.9	11
69	Palliative Chemotherapy Does Not Improve Survival in Metastatic Esophageal Cancer. Oncology, 2010, 79, 46-54.	0.9	20
70	Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer, 2010, 46, 1344-1351.	1.3	118
71	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 942-949.	5.1	260
72	“Sufficient Life Expectancy”: An Amazing Inclusion Criterion in Cancer Phase II-III Trials. Journal of Clinical Oncology, 2009, 27, e105-e105.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?. <i>Oncology</i> , 2009, 77, 157-161.	0.9	2
74	Fluorouracil Should Continue to Be Incorporated in the Treatment of Localized Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 467-468.	0.8	3
75	Cancer-associated hypercalcemia: validation of a bedside prognostic score. <i>Supportive Care in Cancer</i> , 2009, 17, 1133-1135.	1.0	9
76	Publication biases and phase II trials investigating anticancer targeted therapies. <i>Investigational New Drugs</i> , 2009, 27, 287-288.	1.2	9
77	E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1871-1876.	1.3	19
78	Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?. <i>Current Opinion in Oncology</i> , 2009, 21, 360-366.	1.1	11
79	Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients. <i>PLoS ONE</i> , 2009, 4, e6483.	1.1	14
80	Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. <i>Supportive Care in Cancer</i> , 2008, 16, 387-392.	1.0	27
81	Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: In Regard to Safran et al. (<i>Int J Radiat Oncol Biol Phys</i> 2008;70:391-395). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 958-959.	0.4	2
82	Primitive neuroectodermal tumour of the duodenum with unexpected lymph node involvement. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 511-512.	0.6	1
83	Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5335-5343.	0.8	96
84	Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases. <i>Sarcoma</i> , 2008, 2008, 1-6.	0.7	68
85	Recurrent Priapism Related to Oxaliplatin Infusion. <i>Journal of Clinical Oncology</i> , 2008, 26, 1016-1017.	0.8	11
86	Imatinib as a Possible Cause of Severe Rhabdomyolysis. <i>New England Journal of Medicine</i> , 2008, 358, 2746-2747.	13.9	43
87	Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. <i>Gut</i> , 2007, 56, 734-734.	6.1	26
88	Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2007, 73, 185-191.	0.9	6
89	Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 1107-1113.	0.8	359
90	Angiosarcomas and Taxanes. <i>Current Treatment Options in Oncology</i> , 2007, 8, 428-434.	1.3	36

#	ARTICLE	IF	CITATIONS
91	External beam radiation therapy followed by high-dose-rate brachytherapy for inoperable superficial esophageal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1456-1461.	0.4	25
92	Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3562-3569.	0.8	200
93	Randomized Comparison of Prophylactic Antidiarrheal Treatment Versus No Prophylactic Antidiarrheal Treatment in Patients Receiving CPT-11 (Irinotecan) for Advanced 5-FU-Resistant Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 143-148.	0.6	25
94	Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer?. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 161-169.	1.1	7
95	Intestinal involvement in sarcoidosis. <i>Gastroenterology</i> , 1993, 104, 947.	0.6	2
96	Increased Intestinal Permeability in Active Pulmonary Sarcoidosis. <i>The American Review of Respiratory Disease</i> , 1992, 145, 1440-1445.	2.9	38
97	Statistical analysis of crossover studies. <i>Gastroenterology</i> , 1992, 103, 1994.	0.6	3
98	Cervical lymph nodes from an unknown primary tumor in 190 patients. <i>American Journal of Surgery</i> , 1990, 160, 443-446.	0.9	102